← Back to Clinical Trials
Recruiting NCT07032103

NCT07032103 Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07032103
Status Recruiting
Phase
Sponsor Samsung Medical Center
Condition Lymphoma
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2022-06-01
Primary Completion 2028-12-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Immunochemotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2022-06-01 with a primary completion date of 2028-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Eligibility Criteria

Inclusion Criteria: 1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas 2. 20 years 3. Patients requiring systemic chemotherapy with curative intent 4. Written informed consent Exclusion Criteria: 1. Myeloid malignancy 2. Multiple myeloma 3. Patients do not require systemic chemotherapy with curative intent

Contact & Investigator

Central Contact

Seok Jin Kim, MD., PhD.

✉ kstwoh@gmail.com

📞 +82234101766

Frequently Asked Questions

Who can join the NCT07032103 clinical trial?

This trial is open to participants of all sexes, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07032103 currently recruiting?

Yes, NCT07032103 is actively recruiting participants. Contact the research team at kstwoh@gmail.com for enrollment information.

Where is the NCT07032103 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT07032103 clinical trial?

NCT07032103 is sponsored by Samsung Medical Center. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology